Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LYB001 Booster in Adults
NCT05683600Phase 3Terminated
- Sponsor
- Patronus Biotech
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19), sponsored by Patronus Biotech. Started Dec 2022; status: terminated.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05683600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683600.